Trends in Prostate Cancer Incidence and Mortality in Portugal
DOI:
https://doi.org/10.24915/aup.224Keywords:
Prostatic Neoplasms/epidemiology, Prostatic Neoplasms/mortalityAbstract
Introduction: To describe time trends in prostate cancer incidence and mortality in Portugal, overall and by region.Methods: Incidence data were retrieved from the Registos Oncológicos Regionais (RORs) for the period 1998-2010. Mortality data were obtained from the World Health Organization (1980-2003; 2007-2011) and from Statistics Portugal (2004-2006; 2012-2015; 1991-2015 for regional data). JoinPoint analyses were used to identify significant changes in trends in age-standardized incidence (ASIR) and mortality rates (ASMR)
Results: In Portugal, prostate cancer incidence has been increasing since 1998 (1.8%/year), except the northern region, with a decrease since 2005 (-3.6%/year). An overall mortality decline has been observed since 1997 (-2.6%/year) with non-statistically significant variations observed in Beja, Bragança, Castelo Branco, Évora, Guarda, Portalegre, and the autonomous regions of Madeira and Azores. Significant downward trends were observed in the remaining districts; the variation was largest than -2%/year in Braga, Leiria, Porto, Viana do Castelo and Vila Real.
Conclusion: In the present study we updated our previous trend analysis of mortality rates and quantified the variation in incidence rates in Portugal and by region. Despite the overall increasing incidence and decreasing mortality trends, there is a large heterogeneity across regions. Since this represents an important Public Health problem, future studies should address regional differences in the trends in prostate specific antigen (PSA) screening and the effective management of prostate cancer.
Downloads
References
Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer; 2013 [accessed Feb 2023] Available from: http://globocan.iarc.fr.
Bray F, Ferlay J, Laversanne M, Brewster DH, Gombe Mbalawa C, Kohler B, et al. Cancer Incidence in Five Continents: Inclusion criteria, highlights from Volume X and the global status of cancer registration. Int J Cancer. 2015;137:2060-71.
Center MM, Jemal A, Lortet-Tieulent J, Ward E, Ferlay J, Brawley O, et al. International variation in prostate cancer incidence and mortality rates. Eur Urol. 2012;61:1079-92.
Arnold M, Karim-Kos HE, Coebergh JW, Byrnes G, Antilla A, Ferlay J, et al. Recent trends in incidence of five common cancers in 26 European countries since 1988: Analysis of the European Cancer Observatory. Eur J Cancer. 2015;51:1164-87.
Fontes F, Severo M, Castro C, Lourenco S, Gomes S, Botelho F, et al. Model-based patterns in prostate cancer mortality worldwide. Br J Cancer. 2013;108:2354-66.
Malvezzi M, Bertuccio P, Rosso T, Rota M, Levi F, La Vecchia C, et al. European cancer mortality predictions for the year 2015: does lung cancer have the highest death rate in EU women? Ann Oncol. 2015;26:779-86.
Larsen SB, Brasso K, Christensen J, Johansen C, Tjonneland A, Friis S, et al. Socioeconomic position and mortality among patients with prostate cancer: influence of mediating factors. Acta Oncol. 2017;56:563-8. doi: 10.1080/0284186X.2016.1260771.
Heidenreich A, Abrahamsson PA, Artibani W, Catto J, Montorsi F, Van Poppel H, et al. Early detection of prostate cancer: European Association of Urology recommendation. Eur Urol. 2013;64:347-54.
Neupane S, Bray F, Auvinen A. National economic and development indicators and international variation in prostate cancer incidence and mortality: an ecological analysis. World J Urol. 2017;35:851-8. doi: 10.1007/s00345-016-1953-9.
Howrey BT, Kuo YF, Lin YL, Goodwin JS. The impact of PSA screening on prostate cancer mortality and overdiagnosis of prostate cancer in the United States. J Gerontol A Biol Sci Med Sci. 2013;68:56-61.
Kumar S, Shelley M, Harrison C, Coles B, Wilt TJ, Mason MD. Neo-adjuvant and adjuvant hormone therapy for localised and locally advanced prostate cancer. Cochrane Database Syst Rev. 2006;2006:CD006019. doi: 10.1002/14651858.CD006019.pub2.
Instituto Português de Oncologia do Porto Francisco Gentil. RORENO: Registo Oncológico Nacional 2010. IPO-Porto: Porto; 2016.
Portal do Instituto Nacional de Estatística [Internet]. Instituto Nacional de Estatística,. [accessed 15/03/2017]. Available from: http://www.ine.pt/xportal/xmain?xpgid=ine_main&xpid=INE.
GDB Results Tool [Internet]. 2017 [accessed 24/03/2017]. Available from: http://ghdx.healthdata.org/gbd-results-tool.
Bastos J, Botelho F, Pina F, Lunet N. Trends in prostate cancer mortality in Portugal (1980-2006). Acta Med Port. 2011;24:499-504.
Castro C, Antunes L, Lunet N, Bento MJ. Cancer incidence predictions in the North of Portugal: keeping population-based cancer registration up to date. Eur J Cancer Prev. 2016;25:472-80.
Pina F, Castro C, Ferro A, Bento MJ, Lunet N. Prostate cancer incidence and mortality in Portugal: trends, projections and regional differences. Eur J Cancer Prev. 2017;26:404-10.
World Health Organization. International classification of disease and related health problems, 10th revision. Geneva: WHO; 1992.
Instituto Português de Oncologia do Porto Francisco Gentil. RORENO: Registo Oncológico Regional do Norte 2010. Porto: IPO-Porto; 2015.
Instituto Português de Oncologia de Coimbra Francisco Gentil. ROR-Centro: Registo Oncológico Regional Região Centro 2010. Coimbra: ROR-Centro; 2012.
Instituto Português de Oncologia de Lisboa Francisco Gentil. ROR-Sul: Incidência, Sobreviência e Mortalidade por cancro na região sul de Portugal - ISM 2008. Lisboa: IPO-Lisboa; 2014.
ROR-Açores. [Incidências, taxas de incidência, novos casos do cancro nos Açores (2011) - Homens] Angra do Heroísmo, Açores: Serviço Regional de Estatística dos Açores; 2014 [accessed Dec 2022] Available from: http://estatistica.azores.gov.pt/upl/%7B842c0f71-b4e2-4052-8541-f0be4e298476%7D.htm.
Doll R, Smith P. Comparison between registries: age-standardized rates. In: Waterhouse J, Muir C, Shanmugaratnam K, Powell J, Peacham D, Whelan S, editors. Cancer incidence in five continents. IV. Lyon: International Agency for Research on Cancer; 1982. p. 671-5.
World Health Organization, health statistics and information systems, mortality database [Internet]. 2015 [accessed 10/09/2015]. Available from: http://www.who.int/healthinfo/statistics/mortality_rawdata/en/.
Direção Geral da Saúde. Risco de Morrer em Portugal. 1991-2005.
National Cancer Institute. Joinpoint Regression Program 2015. [accessed 10/09/2015] Available from: http://srabcancergov/joinpoint/.
Jemal A, Fedewa SA, Ma J, Siegel R, Lin CC, Brawley O, et al. Prostate Cancer Incidence and PSA Testing Patterns in Relation to USPSTF Screening Recommendations. JAMA. 2015;314:2054-61.
Hoffman RM, Meisner AL, Arap W, Barry M, Shah SK, Zeliadt SB, et al. Trends in United States Prostate Cancer Incidence Rates by Age and Stage, 1995-2012. Cancer Epidemiol Biomarkers Prev. 2016;25:259-63.
Mistry M, Parkin DM, Ahmad AS, Sasieni P. Cancer incidence in the United Kingdom: projections to the year 2030. Br J Cancer. 2011;105:1795-803.
Costa AR, Silva S, Moura-Ferreira P, Villaverde-Cabral M, Santos O, Carmo ID, et al. Cancer screening in Portugal: sex differences in prevalence, awareness of organized programmes and perception of benefits and adverse effects. Health Expect. 2017;20:211-20. doi: 10.1111/hex.12450.
Direção Geral da Saúde. [Prescrição e Determinação do Antigénio Específico da Próstata - PSA; Norma nº 060/2011 de 29/12/2011]. In: DGS - Direção-Geral da Saúde, editor. Norma nº 060/2011 de 29/12/20112014. Lisboa: DGS; 2011.
Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:E359-86.
Dorr M, Holzel D, Schubert-Fritschle G, Engel J, Schlesinger-Raab A. Changes in prognostic and therapeutic parameters in prostate cancer from an epidemiological view over 20 years. Oncol Res Treat. 2015;38:8-14. doi: 10.1159/000371717.
Bansal D, Undela K, D’Cruz S, Schifano F. Statin use and risk of prostate cancer: a meta-analysis of observational studies. PLoS One. 2012;7:e46691. doi: 10.1371/journal.pone.0046691.
Raval AD, Thakker D, Negi H, Vyas A, Kaur H, Salkini MW. Association between statins and clinical outcomes among men with prostate cancer: a systematic review and meta-analysis. Cancer Prostatic Dis. 2016;19:151-62. doi: 10.1038/pcan.2015.58.
Zhong S, Zhang X, Chen L, Ma T, Tang J, Zhao J. Statin use and mortality in cancer patients: Systematic review and meta-analysis of observational studies. Cancer Treat Rev. 2015;41:554-67. doi: 10.1016/j.ctrv.2015.04.005.
Larsen SB, Dehlendorff C, Skriver C, Dalton SO, Jespersen CG, Borre M, et al. Postdiagnosis statin use and mortality in Danish patients with prostate cancer. J Clin Oncol. 2017;35:3290-7. doi: 10.1200/JCO.2016.71.8981.
Ilic D, Neuberger MM, Djulbegovic M, Dahm P. Screening for prostate cancer. Cochrane Database Syst Rev. 2013;2013:CD004720. doi: 10.1002/14651858.CD004720.pub3.
Roobol MJ, Kranse R, Bangma CH, van Leenders AG, Blijenberg BG, van Schaik RH, et al. Screening for prostate cancer: results of the Rotterdam section of the European randomized study of screening for prostate cancer. Eur Urol. 2013;64:530-9.
Global Burden of Disease Cancer C, Fitzmaurice C, Dicker D, Pain A, Hamavid H, Moradi-Lakeh M, et al. The Global Burden of Cancer 2013. JAMA Oncol. 2015;1:505-27.
Loeb S, Bjurlin MA, Nicholson J, Tammela TL, Penson DF, Carter HB, et al. Overdiagnosis and overtreatment of prostate cancer. Eur Urol. 2014;65:1046-55.
Anastasiadis E, van der Meulen J, Emberton M. Hospital admissions after transrectal ultrasound-guided biopsy of the prostate in men diagnosed with prostate cancer: a database analysis in England. Int J Urol. 2015;22:181-6. doi: 10.1111/iju.12634.
Baade PD, Yu XQ, Smith DP, Dunn J, Chambers SK. Geographic disparities in prostate cancer outcomes—review of international patterns. Asian Pac J Cancer Prev. 2015;16:1259-75. doi: 10.7314/apjcp.2015.16.3.1259.
World Health Organization. Global Health Observatory data repository [accessed 2017-04-24]. Available from: http://apps.who.int/gho/data/node.main.121?lang=en/.
Fall K, Stromberg F, Rosell J, Andren O, Varenhorst E. Reliability of death certificates in prostate cancer patients. Scand J Urol Nephrol. 2008;42:352-7.
Penson DF, Albertsen PC, Nelson PS, Barry M, Stanford JL. Determining cause of death in prostate cancer: are death certificates valid? J Natl Cancer Inst. 2001;93:1822-3. doi: 10.1093/jnci/93.23.1822.
Turner EL, Metcalfe C, Donovan JL, Noble S, Sterne JA, Lane JA, et al. Contemporary accuracy of death certificates for coding prostate cancer as a cause of death: Is reliance on death certification good enough? A comparison with blinded review by an independent cause of death evaluation committee. Br J Cancer. 2016;115:90-4.
Published
Issue
Section
Copyright (c) 2023 Portuguese Association of Urology
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
